Persistence, Adherence, and Switching to Higher-Cost Therapy in Patients with Multiple Sclerosis Initiating Oral Disease-Modifying Therapies: A Retrospective Real-World Study

AUTHORS

1*Lita Araujo, MSc, PhD; 1Svend S Geertsen, PhD; 1,2Allen Amedume, PharmD; 1Keiko Higuchi, MPH, PhD; 3Janneke van Wingerden, MSc

AUTHORS’ AFFILIATIONS

1Sanofi, Cambridge, MA, US
2School of Pharmacy, Massachusetts College of Pharmacy and Health Sciences (MCPHS) University, Boston, MA, US
3Sanofi, Amsterdam, The Netherlands

*Corresponding author

Lita Araujo, MSc, PhD, lita.araujo@sanofi.com (ORCID ID: 0000-0002-6863-9340)
Svend Sparre Geertsen, PhD, svend.geertsen@sanofi.com (ORCID ID: 0000-0003-4497-3616)
Allen Amedume, PharmD, allen.amedume@sanofi.com
Keiko Higuchi, MPH, PhD, keiko.higuchi@sanofi.com
Janneke van Wingerden, MSc, janneke.wingerden@sanofi.com
### Supplementary Material Table 1. National Drug Codes for study DMTs

| Generic name       | Brand name | Format             | Dosage | NDCs              |
|--------------------|------------|--------------------|--------|-------------------|
| Teriflunomide      | Aubagio    | Tablet             | 7 mg   | 58468021101       |
|                    |            |                    |        | 58468021104       |
|                    |            |                    | 14 mg  | 58468021002       |
|                    |            |                    |        | 58468021004       |
| Dimethyl fumarate  | Tecfidera  | Delayed-release    | 120 mg | 00378039614       |
|                    |            | capsule            |        | 00093921841       |
|                    |            |                    |        | 24979012721       |
|                    |            |                    |        | 67877055514       |
|                    |            |                    |        | 68180077614       |
|                    |            |                    |        | 16729041604       |
|                    |            |                    |        | 69238131804       |
|                    |            |                    |        | 31722065731       |
|                    |            |                    |        | 69097032289       |
|                    |            |                    |        | 43598042952       |
|                    |            |                    |        | 644060000501      |
|                    |            |                    | 240 mg | 00378039991       |
|                    |            |                    |        | 51407044160       |
|                    |            |                    |        | 00093921906       |
|                    |            |                    |        | 24979012804       |
|                    |            |                    |        | 67877055660       |
|                    |            |                    |        | 68180077707       |
|                    |            |                    |        | 16729041712       |
|                    |            |                    |        | 16729041759       |
|                    |            |                    |        | 69238131906       |
|                    |            |                    |        | 31722065832       |
|                    |            |                    |        | 69097032303       |
|                    |            |                    |        | 43598043060       |
|                    |            |                    |        | 644060000602      |
| Name                        | Brand Name       | Formulation        | Strength  | NDC                |
|-----------------------------|------------------|--------------------|-----------|--------------------|
| Diroximel fumarate          | Vumerity         | Delayed-release    | 231 mg    | 64406002003        |
| Fingolimod                  | Gilenya          | Tablet             | 0.5 mg    | 000780060715       |
| Cladribine                  | Mavenclad        | Tablet             | 10 mg     | 4408704004         |
| Natalizumab                 | Tysabri          | Injectable         | 300 mg/15 mL | 590750073015     |
| Ocrelizumab                 | Ocrevus          | Injectable         | 300 mg/10 mL | 502420015001     |

NDC, national drug code; DMT, disease-modifying therapy.
**Supplementary Material Table 2.** Procedure codes for DMTs administered in the clinical setting

| Generic name | Procedure code          |
|--------------|-------------------------|
| Natalizumab  | C9126 (injection)       |
|              | J2323 (injection, 1mg)  |
| Ocrelizumab  | J2350 (injection, 1mg)  |
|              | C9494 (injection, 1mg)  |

DMT, disease-modifying therapy.